α-Synuclein regulation by chaperones in mammalian cells

Neurodegeneration in patients with Parkinson’s disease is correlated with the occurrence of Lewy bodies—intracellular inclusions that contain aggregates of the intrinsically disordered protein α-synuclein 1 . The aggregation propensity of α-synuclein in cells is modulated by specific factors that include post-translational modifications 2 , 3 , Abelson-kinase-mediated phosphorylation 4 , 5 and interactions with intracellular machineries such as molecular chaperones, although the underlying mechanisms are unclear 6 – 8 . Here we systematically characterize the interaction of molecular chaperones with α-synuclein in vitro as well as in cells at the atomic level. We find that six highly divergent molecular chaperones commonly recognize a canonical motif in α-synuclein, consisting of the N terminus and a segment around Tyr39, and hinder the aggregation of α-synuclein. NMR experiments 9 in cells show that the same transient interaction pattern is preserved inside living mammalian cells. Specific inhibition of the interactions between α-synuclein and the chaperone HSC70 and members of the HSP90 family, including HSP90β, results in transient membrane binding and triggers a remarkable re-localization of α-synuclein to the mitochondria and concomitant formation of aggregates. Phosphorylation of α-synuclein at Tyr39 directly impairs the interaction of α-synuclein with chaperones, thus providing a functional explanation for the role of Abelson kinase in Parkinson’s disease. Our results establish a master regulatory mechanism of α-synuclein function and aggregation in mammalian cells, extending the functional repertoire of molecular chaperones and highlighting new perspectives for therapeutic interventions for Parkinson’s disease. Chaperones interact with a canonical motif in α-synuclein, which can be prevented by phosphorylation of α-synuclein at Tyr39, whereas inhibition of this interaction leads to the localization of α-synuclein to the mitochondria and aggregate formation.

[1]  C. Morris,et al.  Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson’s disease , 2018, npj Parkinson's Disease.

[2]  T. Sharpe,et al.  A molecular mechanism of chaperone-client recognition , 2016, Science Advances.

[3]  Michael Krauss,et al.  Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins , 2014, Science.

[4]  Björn M. Burmann,et al.  Conformation and dynamics of the periplasmic membrane-protein–chaperone complexes OmpX–Skp and tOmpA–Skp , 2013, Nature Structural &Molecular Biology.

[5]  H. Bull,et al.  Surface tension of amino acid solutions: a hydrophobicity scale of the amino acid residues. , 1974, Archives of biochemistry and biophysics.

[6]  Gary J. Pielak,et al.  Macromolecular Crowding in the Escherichia coli Periplasm Maintains α-Synuclein Disorder , 2006 .

[7]  R. Cappai,et al.  The Molecular Chaperone Hsp90 Modulates Intermediate Steps of Amyloid Assembly of the Parkinson-related Protein α-Synuclein* , 2009, The Journal of Biological Chemistry.

[8]  Colin L. Masters,et al.  Neurodegenerative diseases and oxidative stress , 2004, Nature Reviews Drug Discovery.

[9]  I. Korndörfer,et al.  Structure of the periplasmic chaperone Skp suggests functional similarity with cytosolic chaperones despite differing architecture , 2004, Nature Structural &Molecular Biology.

[10]  M. Kabani,et al.  Hsc70 Protein Interaction with Soluble and Fibrillar α-Synuclein* , 2011, The Journal of Biological Chemistry.

[11]  Ad Bax,et al.  Impact of N-Terminal Acetylation of α-Synuclein on Its Random Coil and Lipid Binding Properties , 2012, Biochemistry.

[12]  E. Masliah,et al.  c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. , 2014, Human molecular genetics.

[13]  G. Knott,et al.  The making of a Lewy body: the role of α-synuclein post-fibrillization modifications in regulating the formation and the maturation of pathological inclusions , 2018, bioRxiv.

[14]  E. Mandelkow,et al.  Hsp90-Tau Complex Reveals Molecular Basis for Specificity in Chaperone Action , 2014, Cell.

[15]  N. Ban,et al.  Trigger factor in complex with the ribosome forms a molecular cradle for nascent proteins , 2004, Nature.

[16]  Bernd Bukau,et al.  Substrate specificity of the DnaK chaperone determined by screening cellulose‐bound peptide libraries , 1997, The EMBO journal.

[17]  Nadinath B. Nillegoda,et al.  Human Hsp70 Disaggregase Reverses Parkinson's-Linked α-Synuclein Amyloid Fibrils. , 2015, Molecular cell.

[18]  C. Dobson,et al.  Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/α‐synuclein complex by Hip , 2009, The EMBO journal.

[19]  François-Xavier Theillet,et al.  Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event. , 2014, ACS chemical neuroscience.

[20]  W. V. van IJcken,et al.  Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes , 2019, Nature Neuroscience.

[21]  Philipp Selenko,et al.  Structural disorder of monomeric α-synuclein persists in mammalian cells , 2016, Nature.

[22]  Oliver Hantschel,et al.  Regulation of the c-Abl and Bcr–Abl tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[23]  A. Deniz,et al.  Two-Dimensional Crowding Uncovers a Hidden Conformation of α-Synuclein. , 2016, Angewandte Chemie.

[24]  Christopher M. Dobson,et al.  Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein , 2012, Cell.

[25]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[26]  C. Dobson,et al.  Heat Shock Protein 70 Inhibits α-Synuclein Fibril Formation via Preferential Binding to Prefibrillar Species* , 2005, Journal of Biological Chemistry.

[27]  Yujin E. Kim,et al.  Molecular chaperone functions in protein folding and proteostasis. , 2013, Annual review of biochemistry.

[28]  C. Dobson,et al.  Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers , 2017, Science.

[29]  P. McLean,et al.  Molecular Chaperones and Co-Chaperones in Parkinson Disease , 2012, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[30]  C. Kalodimos,et al.  Structural Basis for Protein Antiaggregation Activity of the Trigger Factor Chaperone , 2014, Science.

[31]  J. Buchner,et al.  The HSP90 chaperone machinery , 2017, Nature Reviews Molecular Cell Biology.

[32]  A. Nunez,et al.  Serum Albumin Prevents Protein Aggregation and Amyloid Formation and Retains Chaperone-like Activity in the Presence of Physiological Ligands , 2012, The Journal of Biological Chemistry.

[33]  J. Troncoso,et al.  Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. , 2016, The Journal of clinical investigation.

[34]  Carolyn M. Sue,et al.  Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives , 2018, Current Neurology and Neuroscience Reports.

[35]  E. Schon,et al.  Novel subcellular localization for α-synuclein: possible functional consequences , 2015, Front. Neuroanat..

[36]  François-Xavier Theillet,et al.  Intracellular repair of oxidation-damaged α-synuclein fails to target C-terminal modification sites , 2016, Nature Communications.

[37]  E. Masliah,et al.  The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.